Monoclonal Antibodies to Coronavirus SARS-CoV-2 RBD Domain

Coronavirus antibody

Experiment Design: Utilizes 2019 novel Coronavirus spike protein receptor binding domain as the immunogens for monoclonal antibody production

Advantages: Chemically synthesized peptides were oxidized to form the correct disulfide bridge. The peptides were folded in a proprietary folding solution to maintain the native protein structure

Progress Update: ELISA to be tested, Hybridoma cell fusion to be performed, Heavy/Light chains to be sequenced, Genes to be constructed, Proteins to be expressed in a mammalian cell lines, Antibodies to be tested and characterized.

Add to Cart:

  • 1 Units in Stock

Copyright © 2020 Powered by LifeTein